xalkori
pfizer europe ma eeig - crizotinib - karsinom, ikke-småcellet lunge - antineoplastiske midler - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.
rivastigmin orion 3 mg
orion corporation - espoo - rivastigminhydrogentartrat - kapsel, hard - 3 mg
rivastigmin orion 1.5 mg
orion corporation - espoo - rivastigminhydrogentartrat - kapsel, hard - 1.5 mg
rivastigmin orion 4.5 mg
orion corporation - espoo - rivastigminhydrogentartrat - kapsel, hard - 4.5 mg
rivastigmin orion 6 mg
orion corporation - espoo - rivastigminhydrogentartrat - kapsel, hard - 6 mg
prograf 0.5 mg
astellas pharma a/s - takrolimusmonohydrat - kapsel, hard - 0.5 mg
prograf 1 mg
astellas pharma a/s - takrolimusmonohydrat - kapsel, hard - 1 mg
prograf 5 mg
astellas pharma a/s - takrolimusmonohydrat - kapsel, hard - 5 mg
bronchitol
pharmaxis europe limited - mannitol - cystisk fibrose - hoste og kalde preparater - bronchitol er indisert for behandling av cystisk fibrose (cf) hos voksne i alderen 18 år og over som en tilleggsbehandling til den beste pasientstandarden.
sevikar 40 mg / 5 mg
daiichi sankyo europe gmbh - olmesartanmedoksomil / amlodipinbesilat - tablett, filmdrasjert - 40 mg / 5 mg